Next, we tested the BG-conjugated FMC63 antibody (FMC63-BG) for its ability to activate synNotch signaling in response to CD19-positive tumor cells (Fig. 2d & Supplementary Fig. S3). This evidence concerns the gene CD19 and neoplasm.